Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Forman, Stephen J  [Clear All Filters]
2019
Herrera, A.F., Chen, L., Khajavian, S., Chase, M., Darrah, J., Maloney, D., Ho, V.T., Soiffer, R.J., Antin, J.H., Forman, S.J., et al. (2019). Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma.Biol Blood Marrow Transplant.
Slavin, T.P., Teh, J.Berano, Weitzel, J.N., Peng, K., F Wong, L., Qin, H., Wang, J., Wu, X., Mei, M., Pillai, R., et al. (2019). Association between Clonal Hematopoiesis and Late Non-Relapse Mortality after Autologous Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.
Stevens, B.M., Zhang, W., Pollyea, D.A., Winters, A., Gutman, J., Smith, C., Budde, E., Forman, S.J., Jordan, C.T., and Purev, E. (2019). CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome.Exp Hematol.
Nakamura, R., Gendzekhadze, K., Palmer, J., Tsai, N.-C., Mokhtari, S., Forman, S.J., Zaia, J.A., Senitzer, D., Marcucci, G., and Stein, A. (2019). Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.Leuk Res87, 106230.
Malki, M.M.Al, Gendzekhadze, K., Yang, D., Mokhtari, S., Parker, P., Karanes, C., Palmer, J., Snyder, D., Forman, S.J., Nademanee, A., et al. (2019). Long-term outcome of allogeneic hematopoietic stem cell transplantation from unrelated donor using tacrolimus/sirolimus-based GVHD prophylaxis: impact of HLA mismatch.Transplantation.
Mei, M., Gupta, R., O'Donnell, M., Malki, M.M.Al, Aldoss, I., Ali, H., Farol, L., Snyder, D., Forman, S.J., Nakamura, R., et al. (2019). Post-allogeneic eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with PNH clones.Biol Blood Marrow Transplant.
Jabbour, E.J., Gökbuget, N., Kantarjian, H.M., Thomas, X., Larson, R.A., Yoon, S.-S., Ghobadi, A., Topp, M.S., Tran, Q., Franklin, J.L., et al. (2019). Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.Cancer.